We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for mecasermin (Ipsen Pty Ltd)
Active ingredients
mecasermin
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection, solution
Indication
Mecasermin is indicated for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD).
Therapeutic area
Endocrinology